China Regenerative Medicine International Limited (8158) AI Stock Analysis

• Market Cap: HK$197.76M
• Dividend Yield: N/A
• Average Volume (3M): 243.19K
• Price to Earnings (P/E): 11.1
• Beta (1Y): 0.27
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 304,252,470
• 10 Day Avg. Volume: 263,927
• 30 Day Avg. Volume: 243,187
• PEG Ratio: 0.07
• Price to Book (P/B): 5.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -926.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$0.50 ▼(-23.08%Downside)

The overall stock score of 52 reflects a company with potential upside but significant risks. The financial performance is the primary concern due to revenue volatility, high leverage, and cash flow issues. Technical indicators suggest bullish momentum but caution is advised given the nearing overbought conditions. Valuation is fair, though lack of dividend yield limits appeal for some investors.

China Regenerative Medicine International Limited Business Overview & Revenue Model

Company Description

China Regenerative Medicine International Limited (8158) is a biotechnology company focused on the research, development, and commercialization of innovative regenerative medicine products and technologies. The company operates primarily in the field of tissue engineering, cell therapy, and stem cell research, offering solutions aimed at improving healthcare outcomes. Its core products include skin and organ regeneration products, as well as other advanced medical technologies designed to address unmet medical needs.

How the Company Makes Money

China Regenerative Medicine International Limited generates revenue through the sale of its proprietary regenerative medicine products and technologies. The company's key revenue streams include the commercialization of its tissue engineering and cell therapy products, which are used in medical procedures and treatments. Additionally, the company may form strategic partnerships with healthcare institutions, research organizations, and other biotech companies to expand its market reach and enhance its product offerings. Revenue is further supported by licensing agreements and collaborations that leverage the company's expertise in regenerative medicine, allowing for shared research and development efforts and the potential for milestone and royalty payments.

China Regenerative Medicine International Limited Financial Statement Overview

Summary

The company has shown some recovery in profitability with a return to positive net income in 2024 and improved gross profit margin. However, revenue volatility, high leverage indicated by a debt-to-equity ratio of 2.13, and zero operating and free cash flow in 2024 highlight significant financial challenges and risks.

Income Statement

The company has shown improvement in recent years with a return to positive net income in 2024, following a significant loss in 2023. The gross profit margin increased from 27.9% in 2023 to 63.6% in 2024, indicating better cost management. However, revenue has been volatile, with a decline from 2022 to 2023 and a recovery in 2024, yet still below 2021 levels. This instability in revenue and profitability reflects ongoing challenges.

Balance Sheet

The debt-to-equity ratio is notably high at 2.13 in 2024, indicating significant leverage. Stockholders' equity has improved from 2023 to 2024, but remains a concern due to historical volatility. The equity ratio is low at 18.6%, suggesting limited financial cushion. The overall balance sheet reflects a company with high leverage and risk.

Cash Flow

The company reported zero operating and free cash flow in 2024, indicating potential liquidity issues. Despite positive operating cash flow in 2023, the lack of consistent free cash flow is concerning. The inability to sustain positive cash flows may limit growth opportunities and financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	90.62M	69.49M	41.54M	282.90M	182.14M
Gross Profit	57.65M	19.42M	37.62M	67.73M	41.81M
EBITDA	29.84M	-95.40M	14.44M	64.66M	-121.84M
Net Income	17.75M	-107.70M	4.55M	51.83M	-404.23M
Balance Sheet
Total Assets	135.71M	185.90M	275.91M	259.14M	152.49M
Cash, Cash Equivalents and Short-Term Investments	57.45M	3.33M	1.85M	9.93M	4.77M
Total Debt	53.69M	50.19M	72.01M	35.82M	43.19M
Total Liabilities	110.51M	174.10M	172.00M	147.41M	207.64M
Stockholders Equity	25.20M	11.79M	103.92M	111.73M	58.13M
Cash Flow
Free Cash Flow	17.68M	6.06M	-20.25M	-3.83M	-397.74M
Operating Cash Flow	18.30M	6.34M	-17.65M	-3.02M	-397.74M
Investing Cash Flow	-622.00K	-262.00K	-2.59M	9.27M	326.96M
Financing Cash Flow	2.37M	-7.36M	7.32M	-1.39M	67.37M

China Regenerative Medicine International Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8158, the sentiment is Positive. The current price of 0.65 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.42, and above the 200-day MA of 0.36, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 72.33 is Negative, neither overbought nor oversold. The STOCH value of 76.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8158.

China Regenerative Medicine International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0690	73 Outperform	HK$643.37M	8.00	28.40%	2.56%	14.08%	21.62%
Sector *	59 Neutral	HK$15.54B	5.54	-7.44%	4.07%	11.55%	-28.15%
2197	54 Neutral	HK$382.63M	―		―	-1.73%	-689.53%
2257	54 Neutral	HK$611.02M	―	-266.90%	―	―	31.23%
8158	52 Neutral	HK$197.76M	11.13		―	―	―
6628	51 Neutral	HK$713.47M	―	-32.59%	―	-79.65%	37.50%
1228	51 Neutral	HK$288.89M	―		―	-18.57%	-14.06%